Additionally, in vivo studies in aged animals and other animal models, followed by well-controlled clinical trials, are needed to confirm FAGAE’s acetylcholinesterase activity relative to conventional anti-AD drugs. The gene discussed is ACHE; the disease is Alzheimer disease.